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Abstract Objectives: Because impaired renal function is
detrimental for the conversion of calcidiol to calcitriol
(D-hormone) and since D-hormone analogues have been
shown to decrease the risk of falls, we investigated
whether creatinine clearance (CrCl) is associated with
the number of fallers and falls in elderly men and wo-
men. Methods: Within a randomized controlled study,
we observed for 36 weeks 186 placebo-treated commu-
nity-dwelling elderly men and women over 70, in an
attempt to determine the inﬂuence of baseline CrCl on
calcitropic hormone serum levels, as well as the inﬂuence
of baseline CrCl on the number of fallers and falls over
time. With the help of questionnaires, we regularly as-
sessed fall incidence and frequency. The risk of falls and
the risk of becoming a faller were assessed in multivar-
iate-controlled logistic regression models according to a
cutoﬀ value of the CrCl set at 65 ml/min. Results: At
baseline, serum levels of 1.25(OH)2D3 and iPTH were, in
multivariate-controlled analyses, signiﬁcantly associated
with CrCl (p<0.0001, p=0.001, respectively), whereas
serum levels of 25(OH)D3 were not associated with
CrCl. Below a CrCl of 65 ml/min, 1.25(OH)2D3 serum
levels steadily declined. We therefore chose a CrCl of
65 ml/min as cutoﬀ for further analyses. During the
36 weeks of observation, elderly people with a CrCl of
<65 ml/min had, in multivariate controlled analyses,
compared with elderly with a CrCl of ‡65 ml/min, a
signiﬁcantly higher incidence of number of fallers (25/70
vs 21/116; OR=4.01; 95% CI, 1.48–10.98; p=0.006),
and a signiﬁcantly higher incidence of falls (28/70 vs 23/
116; OR=3.68; 95% CI, 1.38–9.82; p=0.009). Conclu-
sions: For the ﬁrst time we showed that in a community-
dwelling population of elderly men and women, a CrCl
of less than 65 ml/min is a signiﬁcant and independent
risk factor for fallers and falls.
Keywords Creatinine clearance Æ Elderly Æ Fallers Æ
Falls Æ D-Hormone
Introduction
The risk of falling increases with aging. In elderly men
and women, falls are, independent of the increased
incidence of fall-related fractures [1, 2], associated with
loss of independence [3], deterioration of quality life,
and increased mortality [4]. Several studies have inves-
tigated the risk factors for falls in the elderly [5, 6, 7].
Among others, vitamin D deﬁciency and/or low
D-hormone (calcitriol/1,25(OH)2D3), associated with a
decrease of muscle strength [8, 9, 10, 11], decreased
balance [8, 12, 13], and loss of functional mobility [13,
14], are more and more recognized to be important risk
factors for falls in the elderly. Several recently published
studies have shown that supplementation of vitamin D
in vitamin D–deﬁcient institutionalized women [15] and
treatment with either calcitriol in osteopenic vitamin
D–replete women [16] or alfacalcidol, a D-hormone
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prodrug, in a population of community-dwelling elderly
non–vitamin D–deﬁcient men and women [17] can sig-
niﬁcantly reduce frequency of falls [15, 16, 17] and
number of fallers [17].
The conversion of calcidiol (25(OH)D3) to the met-
abolically most active form of vitamin D, the D-hor-
mone (calcitriol/1.25(OH)2D3), is highly dependent on
the creatinine clearance [18, 19]. It is hypothesized that
below a creatinine clearance of 60 ml/min [20] or 50 ml/
min [21], the renal conversion of 25(OH)D3 to
1.25(OH)2D3 becomes insuﬃcient [20, 21]. Several
studies [8, 9, 22] suggest that even a slight decrease in
1.25(OH)2D3 and a corresponding slight increase in
iPTH serum levels, observed when creatinine clearance
(CrCl) decreases to 60–80 ml/min [23], is associated with
subclinical myopathy and balance trouble. It is nowa-
days accepted that the related increased occurrence of
falling, together with increased skeletal fragility, has a
larger eﬀect on age-related increased frequency of frac-
tures than bone mass alone [22, 24]. According to the
currently published updated K/DOQL (Kidney disease
outcomes quality initiative guidelines by the US Kidney
Foundation) [25], a slight decrease of the CrCl is asso-
ciated with a decrease in bone mineral density [26], and
since a CrCl below 60 ml/min increases signiﬁcantly the
risk of fractures, the guidelines suggest an intensive
control of patients with decreased creatinine clearance
[25, 26].
Aging is associated with a deterioration of renal
function, easily measurable as deterioration of the
creatinine clearance, and several studies suggest that a
signiﬁcant number of elderly people, even with
normal vitamin D serum levels (>12 ng/ml), may suﬀer
from a deﬁciency of 1.25(OH)2D3 [27, 28, 29], due to the
age-related impaired renal function and the consecu-
tively decreased activity of the renal 1a-hydroxylase [21,
30].
Since aging is associated with a decreasing creatinine
clearance and consequently with decreased serum
levels of 1.25(OH)2D3 and since low 1.25(OH)2D3 serum
levels have been associated with risk of falls, we inves-
tigated whether creatinine clearance is a risk factor for
falls.
Subjects and methods
Participants
This investigation was conducted as post hoc subanal-
ysis in the framework of the Swiss Aims Study [17]. The
Aims study was a large double-blind placebo-controlled
randomized study to assess the inﬂuence of alfacalcidol
(1-alpha-dihydroxy-cholecalcitriol, Bondiol; GRY
Pharma, Germany), a 1.25(OH)2D3 prodrug, on fre-
quency of fallers and falls in community-dwelling elderly
men and women, 70 years old and older. The follow-up
was 36 weeks. The subjects of this investigation were the
186 participants randomized to placebo, comprising 90
men and 96 women [17]. All subjects underwent a
medical examination and biochemical tests, and an-
swered a food frequency questionnaire. Falls were as-
sessed every 12 weeks after the baseline visit for a total
of 36 weeks. Details of assessment of falls were de-
scribed previously [17]. The protocol of this study was
approved by the Ethical Review Board of the University
of Basel and all participants provided written informed
consent. The Data, Safety and Monitoring Board
established by GWD Consult Germany (Safety and
Monitoring Board, GWD Consult, Research Contract,
Postfach 1210, 63152, Mu¨lheim/Main, Germany) re-
viewed the conduct of the study.
Methods
The dietary calcium and vitamin D intake was estimated
by using a food frequency questionnaire, which also
produced information on some demographic, lifestyle,
and nutritional parameters [17]. Calcium was not sup-
plied, none of the participants were receiving physical
therapy or training programs at study entry, and no
attempt was made to alter subjects’ diets or physical
activity during the study. Each subject was asked to keep
a diary on fall incidence and to inform the study center
by a telephone call within 48 h. At each study-site visit,
data on fall incidence were reassessed (date, time, cir-
cumstances, injuries) by trained study nurses using an
interview-administered, not validated, questionnaire.
Falls were deﬁned as ‘‘unintentionally coming to rest on
the ground, ﬂoor, or other lower level.’’ With the per-
mission of the participants all case reports of fall inci-
dences were collected from the house physician or
hospitals. In all subjects, blood samples were drawn for
measurement of serum calcium, phosphate, creatinine,
25(OH)D3, 1.25(OH)2D3, and iPTH. Serum levels of
25(OH)D3, 1.25(OH)2D3, and iPTH were measured by
radioimmunoassay (Nichols): intra-assay variation was
5.1%, 5.0%, and 1.8; interassay variation was 7.9%,
10.8%, and 5.6%. All samples were immediately frozen
at –80C and analyzed by the same person in one batch.
Normal ranges for adults were for iPTH <65 pg/ml, for
25(OH)D3 12–124 ng/ml, and for 1.25(OH)2D3 30–
76 pmol/l. Creatinine clearance was calculated with the
widely accepted formula from Cockroft et al., adjusted
for gender [31].
The statistical analyses were conducted using the SAS
statistical software package, version 8.2, by the SAS
Institute, Cary, NC, USA, licensed to the University of
Basel, Switzerland. Comparisons of means were per-
formed by multivariate-adjusted analyses of variance
[32]. Since iPTH, 25(OH)D3, and 1.25(OH)2D3 distri-
butions were markedly skewed, logarithmic transfor-
mations of these variances were performed prior to
analyses. The relationship between 1.25(OH)2D3 and
creatinine clearance was studied by multivariate-ad-
justed linear regression analyses. The determination of
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the appropriate cutoﬀ point for the CrCl to be used for
further analyses was determined using a receiver oper-
ating characteristic (ROC) curve [33]. Five percent sig-
niﬁcance level was maintained throughout these
analyses, and all tests were two-sided.
Results
General
The mean age of the slightly overweight (mean BMI
26.7 ± 4.1 kg/m2) participants was 75 years
(75.0 ± 4.1) (Table 1). Mean laboratory values for
iPTH, 25(OH)D3, 1.25(OH)2D3, and albumin serum
levels were within the normal range, the mean creatinine
clearance was slightly reduced (78.0 ± 20.3 ml/min)
(Table 1).
Associations between creatinine clearance and
calcitropic hormones, calcium and phosphate serum
levels
Serum levels of 25(OH)D3 were not associated with
creatinine clearance (p=0.62) (Fig. 1). Serum levels of
1.25(OH)2D3 were signiﬁcantly associated with creati-
nine clearance (p<0.001) (Fig. 2). In the ROC analysis
of the association between 1.25(OH)2D3 and the cre-
atinine clearance, the cutoﬀ value for the creatinine
clearance came out to be at 65 ml/min. Below a cre-
atinine clearance of 65 ml/min, 1.25(OH)2D3 serum
levels steadily declined (Fig. 2), and participants with a
creatinine clearance of less than 65 ml/min had signif-
icantly lower mean 1.25(OH)2D3 serum levels than
participants with a creatinine clearance above 65 ml/
min (p=0.001) (Table 2). We therefore chose a creati-
nine clearance of 65 ml/min as a cutoﬀ level for our
further analyses and participants were accordingly
classiﬁed in two groups (creatinine clearance <65 ml/
min vs ‡65 ml/min). In the group with a creatinine
clearance of <65 ml/min, 7% had a creatinine clear-
ance of <40 ml/min. For the other controlled vari-
ables, we found no signiﬁcant diﬀerences between
groups (Table 2).
Association between creatinine clearance and number
of fallers and number of falls
The multivariate analyses included predictors which
have been previously shown to be associated with in-
creased risk of falling or variables which were sig-
niﬁcantly diﬀerent between participants with a
creatinine clearance ‡65 ml/min and those with a cre-
atinine clearance of <65 ml/min. These variables were
Table 1 Characteristics of the study participants (N=186). BMI
body mass index, iPTH intact parathormone
Characteristics
Gender, number of males/females 90/96
Age, years (mean ± SD) 75.0±4.1
BMI, kg/m2 (mean ± SD) 26.7±4.1
Laboratory (mean ± SD)
iPTH, pg/ml 39.1±24.5
1.25(OH)2D3, pg/ml 39.1±10.9
25(OH)D3, ng/ml 28.3±10.7
Albumin, g/l 42.3±3.1
Creatinine clearance, ml/min 78.0±20.3
Fig. 1 Association between 25(OH)D3 (calcidiol) serum levels and
creatinine clearance
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age, gender, body mass index (BMI), number of falls in
previous 3 months, physical activity (sport yes/no),
heart rate at baseline (<80 beats/min vs ‡80 beats/min),
Charlson comorbidity index, dietary calcium intake,
iPTH (pg/ml), 25 (OH)D3 (ng/ml), 1,25 (OH)2D3 (pg/
ml), and albumin (g/l) serum levels at baseline, changes
of iPTH (pg/ml), 25 (OH)D3 (ng/ml), and 1,25 (OH)2D3
(pg/ml) serum levels over time, total number of medi-
cations (N), use of phenprocoumon, estrogen, and
diuretics, coﬀee intake, and intake of multivitamins.
Number of comorbidities was assessed with the Charl-
son comorbidity index and was also included as a con-
trol variable in the analyses.
During the 36 weeks of observation, the elderly
community-dwelling men and women with a creatinine
clearance of <65 ml/min had, in multivariate-controlled
analyses, compared with the participants with a creati-
nine clearance of ‡65 ml/min, a signiﬁcantly higher
incidence of number of fallers (25 out of 70 vs 21 out of
116; OR=4.01; 95% CI, 1.48–10.89; p=0.006) and a
signiﬁcantly higher incidence of falls (28 falls in 70 el-
derly vs 23 falls in 116 elderly; OR=3.68; 95% CI, 1.38–
9.82; p=0.009) (Table 3).
Discussion
We observed a signiﬁcant relationship between creati-
nine clearance (CrCl) and 1.25(OH)2D3 serum levels. We
found no association between CrCl and 25(OH)D3
serum levels. In our population, a creatinine clearance of
less than 65 ml/min (low creatinine clearance) was
associated with declining 1.25(OH)2D3 serum levels. A
creatinine clearance of less than 65 ml/min is considered
a modest impairment of kidney function. Whereas,
participants with a low creatinine clearance had signiﬁ-
cantly lower mean 1.25(OH)2D3 serum levels than par-
ticipants with a creatinine clearance of ‡65 ml/min,
mean serum levels of 25(OH)D3 and iPTH were not
signiﬁcantly diﬀerent between groups. Other authors
found similar relationships between 1.25(OH)2D3 and
creatinine clearance [20, 21]. Francis et al. observed in
women with normal calcidiol serum levels, low
1.25(OH)2D3 serum levels (deﬁned as <31 pg/ml) with a
creatinine clearance below 50 ml/min [21].
Deﬁciency values for vitamin D, and accordingly low
values for 1.25(OH)2D3 (D-hormone/calcitriol), were
established based on the concept of the classic deﬁciency
diseases. However, functional parameters that have been
related to vitamin D and 1.25(OH)2D3 decline at serum
levels which are above the deﬁned deﬁciency levels.
Serum concentrations of 1.25(OH)2D3, which are sig-
niﬁcantly above the lowest deﬁned normal value of
1.25(OH)2D3, respectively associated increases in iPTH
serum levels, have been shown to have a negative impact
on muscle strength and functional mobility [8, 9] and
have been related to myopathy [9, 10, 11, 28, 34]. Serum
levels of 1.25(OH)2D3 have been associated with de-
creased muscle strength, lower endurance [8, 9, 10, 11,
12], reduced functional mobility [13, 14], and atrophy of
fast-twitch muscle ﬁbers [35]. Also, 1.25(OH)2D3 is an
eﬀective treatment of the iPTH-related decrease of en-
ergy metabolism in skeletal muscle and proteolysis of
muscle proteins [36, 37, 38]. Low 1.25(OH)2D3 serum
Fig. 2 Association between 1.25(OH)2D3 (D-hormone) serum
levels and creatinine clearance
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levels and related high normal iPTH levels have been
associated with subclinical myopathy [10, 11, 39]. In one
study, 1.25(OH)2D3 has been shown to reduce the re-
lease of interleukin 6 (IL-6) from human blood mono-
cytes, while 25(OH)D3 was ineﬀective [40]. In another
study, 1.25(OH)2D3 increased insulin-like growth factor
(IGF-I) in vivo [41]. Both factors—increasing IL-6 and
decreasing IGF-I—are synergistic risk factors for func-
tional disability [42]. The results from these studies
[9, 10, 11, 28, 29, 30, 40, 41, 42] suggest that
1.25(OH)2D3 is an independent risk factor for decreased
muscle strength [12, 13], reduced functional mobility
[14], and for falls [8, 16, 17, 43], suggesting a direct
involvement of 1.25(OH)2D3 in the causal pathogenic
pathway of decreased muscle strength-related falls [39].
Speciﬁc receptors for 1.25(OH)2D3 have been found
in muscle tissue [44, 45]. Sorenson et al. showed that
fast-twitch type II muscle ﬁbers atrophy in the absence
of 1.25(OH)2D3 and reappear by treatment with alfa-
calcidol [35]. Analogues of 1.25(OH)2D3 (D-hormone)
have been shown to have an eﬀect on muscle power and
neuromuscular coordination [39, 43, 46, 47, 48]. The
results of these studies, as well as our ﬁnding that the
only signiﬁcant diﬀerence in participants with a low
creatinine clearance compared with participants with a
creatinine clearance of ‡ 65 ml/min was the diﬀerence in
mean 1.25(OH)2D3 serum levels, suggest that the main
vitamin D–dependent eﬀect on muscle and locomotion
comes from the most active form of vitamin D, the
1.25(OH)2D3 (D-hormone). We therefore conclude that
our observed approximately four times increased risk of
falls observed in participants with a low creatinine
clearance is due to a creatinine clearance–dependent
decrease in 1.25(OH)2D3 serum levels. A creatinine
clearance below 65 ml/min can be considered as a sur-
rogate parameter for low 1.25(OH)2D3 serum levels.
Treatment options for patients should therefore clearly
diﬀerentiate between the nutritive vitamin D deﬁciency
and the metabolic low D-hormone syndrome.
Several risk assessment tools are proposed for the
detection of elderly with an increased risk for falls and
for preventive intervention. These tools are mostly used
in fall assessment clinics because they are time con-
suming and need a trained risk assessment team. These
risk assessment tools help to identify several risk factors
for falls and oﬀer the possibility of multifactorial inter-
vention. While several studies have shown that multi-
factorial intervention may prevent falls, other studies
have shown that multifactorial interventions are not
appropriate for all elderly and that they fail in pre-
venting falls [49, 50]. In general, the determination of the
creatinine clearance is of great clinical utility in the
identiﬁcation of elderly with an increased risk for falls
since its determination oﬀers multiple advantages.
Compared with the determination of 1.25(OH)2D3, the
measurement of serum creatinine to calculate creatinine
Table 3 Multivariate OR for number of fallers and falls in elderly
men and women during 36 weeks of observation, according to a
creatinine clearance of <65 ml/min vs ‡65 ml/min. OR odds ratio,
95% CI 95% conﬁdence interval
Multivariate
adjusteda
OR (95% CI)
p Value
Fallers 4.01 (1.48–10.98) 0.006
Falls 3.68 (1.38–9.82) 0.009
aAdjusted for age, gender, BMI, physical activity, iPTH, calcidiol,
D-hormone, and albumin serum levels at baseline; changes of
iPTH, 25(OH)D3, and 1.25(OH)2D3 serum levels over observation
time; use of phenprocoumon, estrogens, diuretics, and multivita-
mins; number of comorbidities, total number of medications, coﬀee
intake, physical activity, and previous falls
Table 2 Characteristics of the
study participants at baseline
according to creatinine
clearance (CrCl). BMI body
mass index, iPTH intact
parathormone, QUS
quantitative ultrasound
(calcaneus)
CrCl <65 ml/min
(N=70)
CrCl ‡65 ml/min
(N=116)
p Value
Gender, number of males/females 28 / 42 62 / 54 0.075
Age, years (mean ± SD) 76.6±4.6 74.0±3.4 <.0001
BMI, kg/m2 (mean ± SD) 24.7±3.0 28.0±4.2 <.0001
Laboratory (mean ± SD)
iPTH, pg/ml 40.9±32.5 38.0±18.0 0.331
1.25(OH)2D3, pg/ml 37.9±12.4 40.6±9.7 0.001
25(OH)D3, ng/ml 27.2±10.9 29.0±10.5 0.184
Albumin, g/l 42.1±3.0 42.7±3.2 0.167
Calcium, mmol/l 2.31±0.09 2.30±0.11 0.502
Phosphate, mmol/l 1.02±0.20 0.98±0.18 0.178
Drug intake
Multivitamin use prior to the study 11.4% 3.5% 0.032
Estrogen use 10.0% 11.2% 0.797
Use of diuretics 17.1% 13.8% 0.536
Other variables (in % or mean ± SD)
Participants experiencing a fall in
the 3 months prior to study entry
22.9% 16.4% 0.536
Regular physical activity 31.4% 45.7% 0.055
Daily dietary calcium intake, mg 512±196 530±167 0.353
Bone Quality QUS, T-score )0.84±1.79 )0.54±1.34 0.256
Timed up & go test, seconds 7.1±1.9 6.9±1.5 0.918
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clearance is easy, cheap, and independent of seasonal or
diurnal variations.
In our study, elderly men and women with a creati-
nine clearance below 65 ml/min had, in multivariate-
controlled analyses, a fourfold increased risk to become
fallers and a 3.7-fold increased risk for falls, during an
observation time of 36 weeks. In a retrospective analysis
of an observational, not-yet-published study in Ger-
many on incidence of osteoporosis, falls, and creatinine
clearance among 5,441 German osteoporotic women
and men aged 60–92 years, based on our cutoﬀ value of
65 ml/min, a low creatinine clearance was compared
with a creatinine clearance of ‡65 ml/min also associated
with an increased risk for falls and fractures (E. Schacht,
Metabolic Bone Disease Unit. Universita¨tsklinik Bal-
grist, Zurich, Switzerland, personal communication).
We are the ﬁrst to show that a low creatinine clearance
is associated with an increased risk of falls.
Our results have several limitations. The results come
from post hoc analyses. The participants were Caucasian
community-dwelling men and women over the age of 70,
so our ﬁndings are not generalizable to a younger pop-
ulation, to the institutionalized elderly, or to men and
women of other races. Since our analyses were done with
participants who received placebo during 36 weeks, we
can not rule out an inﬂuence in either direction of pla-
cebo on risk of falls. Assessment of risk factors for falls,
as well as the large part of the incidence of falls, during
the study was based only on the participant’s own re-
port. Finally we can not exclude uncontrolled con-
founding.
In conclusion, a low creatinine clearance of <65 ml/
min, as a surrogate parameter for low creatinine clear-
ance–associated low 1.25(OH)2D3 serum levels, is a
signiﬁcant, independent, and easily measurable risk
factor for falls, associated with a fourfold increased risk
to become a faller and a 3.7-fold increased risk to
experience a fall.
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